Ketoprofen transdermal - Imprimis Pharmaceuticals

Drug Profile

Ketoprofen transdermal - Imprimis Pharmaceuticals

Alternative Names: Impracor; Ketotransdel; TDLP-110

Latest Information Update: 24 Jun 2014

Price : $50

At a glance

  • Originator Imprimis Pharmaceuticals
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute pain

Most Recent Events

  • 28 Mar 2014 Discontinued - Phase-III for Acute pain in USA (Transdermal)
  • 12 Nov 2013 Imprimis withdraws a phase III trial in Acute pain prior to enrolment in USA (NCT01890902)
  • 18 Apr 2013 Imprimis Pharmaceuticals plans a phase III trial for Acute pain (9148590; NCT01890902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top